On the heels of Addyi's approval, Sprout scooped up by Valeant
Valeant Pharmaceuticals International Inc. is paying $1bn in cash--$500mm up front and $500mm in Q1 2016--to acquire Sprout Pharmaceuticals Inc. and gets a share of future profits upon achievement of certain milestones.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com